Last reviewed · How we verify
Bepreve 1.5% Ophthalmic Solution
At a glance
| Generic name | Bepreve 1.5% Ophthalmic Solution |
|---|---|
| Sponsor | Minnesota Eye Consultants, P.A. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+ (PHASE1)
- Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis Treatment (PHASE4)
- The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer (PHASE4)
- Comparing Patient Satisfaction With Pataday or Bepreve (NA)
- Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis (PHASE2, PHASE3)
- Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers (PHASE3)
- Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis (PHASE3)
- Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bepreve 1.5% Ophthalmic Solution CI brief — competitive landscape report
- Bepreve 1.5% Ophthalmic Solution updates RSS · CI watch RSS
- Minnesota Eye Consultants, P.A. portfolio CI